Cytokinetics challenges Bristol Myers Squibb's patent in court
Cytokinetics has filed a lawsuit against Bristol Myers Squibb seeking to invalidate a recently granted patent. The legal action escalates their existing market rivalry in the cardiovascular drug space. The case centers on patent protection for a competing therapy.
Related stories
Federal court upholds Medicare drug price negotiation program against Merck's challenge · Healthcare systems
Eli Lilly Cracks Down on Illicit Retatrutide Sales · Drug development
Lilly Sues Six Firms Over Unauthorized Sales of Experimental Obesity Drug · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Cytokinetics brings patent suit against Bristol Myers Squibb, escalating rivalry.” Browse more stories.